$CLLS news
The latest CLLS stock news: headlines, filings, AI summaries and sentiment for $CLLS, updated around the clock.
- Pomerantz Law Firm Investigates Cellectis S.A. Following Strategic Pivot and Stock Decline
- Cellectis Exits Two CAR-T Programs, Shifts Focus to Gene Editing for Lipid Disorders
- Cellectis Receives FDA RMAT Designation for Leukemia CAR-T Candidate Lasme-cel
- Cellectis to Participate in Four Investor Conferences in September 2022